Zobrazeno 1 - 5
of 5
pro vyhledávání: '"E K Zilber"'
Autor:
P K Yablonskiy, T I Vinogradova, Yu N Levashev, M V Pavlova, E K Zilber, A A Starshinova, N V Sapozhnikova, I V Chernokhaeva, L I Archakova, N V Zabolotnykh, M L Vitovskaya
Publikováno v:
Терапевтический архив, Vol 88, Iss 3, Pp 111-115 (2016)
The paper sets forth the stages of design and introduction of the new Russian tuberculosis (TB) drug perchlozon registered in the Russian Federation in 2012. Based on the results of Phases I-III clinical trials, the authors evaluate the efficacy and
Externí odkaz:
https://doaj.org/article/fb038c632bd145359e573e43d0d89e97
Publikováno v:
Инфекция и иммунитет, Vol 10, Iss 4, Pp 782-788 (2020)
Current century has been highlighted with rise in allergic pathology, and environment markedly affects it via epigenetic mechanisms. Allergy research in Russia and Finland has been conducted for many years, of larger scale recorded in the latter, sti
Externí odkaz:
https://doaj.org/article/b162dd1f6c5644398962ba4a7d5196b7
Autor:
M. V. Pavlova, N. V. Sapozhnikova, L. I. Archakova, P. V. Gavrilov, A. A. Starshinova, E. K. Zilber
Publikováno v:
Tuberkulez i Bolezni Lëgkih, Vol 0, Iss 3, Pp 67-71 (2014)
Therapy in pregnant women with tuberculosis always presents certain difficulties and sets regarding not only the status of the mother, but also that of her baby. Tuberculosis and pregnancy have been mostly recently considered to be incompatible. The
Autor:
M. V. Pavlova, E. K. Zilber, I. B. Savin, L. I. Archakova, P. V. Gavrilov, P. K. Yablonsky, O. A. Tamm, O. S. Volodich, L. D. Kiryukhina
Publikováno v:
Russian Pulmonology. :65-68
Autor:
T. I. Vinogradova, N. V. Sapozhnikova, Yu. N. Levashev, Piotr Yablonskiy, I. V. Chernokhaeva, M. L. Vitovskaya, N. V. Zabolotnykh, Pavlova Mv, A. A. Starshinova, E. K. Zilber, Ludmila Archakova
Publikováno v:
Терапевтический архив, Vol 88, Iss 3, Pp 111-115 (2016)
ResearcherID
ResearcherID
The paper sets forth the stages of design and introduction of the new Russian tuberculosis (TB) drug perchlozon registered in the Russian Federation in 2012. Based on the results of Phases I-III clinical trials, the authors evaluate the efficacy and